Beam Therapeutics Inc BEAM-X:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:45 PM EDT
24.49quote price arrow up+0.18 (+0.74%)
Volume
195,948
Close
24.31UNCH (UNCH)
Volume
1,518,250
52 week range
16.95 - 49.50
Loading...
  • Open24.19
  • Day High24.78
  • Day Low24.05
  • Prev Close24.31
  • 52 Week High49.50
  • 52 Week High Date02/27/24
  • 52 Week Low16.95
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap1.985B
  • Shares Out81.66M
  • 10 Day Average Volume1.51M
  • Dividend-
  • Dividend Yield-
  • Beta1.84
  • YTD % Change-10.69

KEY STATS

  • Open24.19
  • Day High24.78
  • Day Low24.05
  • Prev Close24.31
  • 52 Week High49.50
  • 52 Week High Date02/27/24
  • 52 Week Low16.95
  • 52 Week Low Date10/23/23
  • Market Cap1.985B
  • Shares Out81.66M
  • 10 Day Average Volume1.51M
  • Dividend-
  • Dividend Yield-
  • Beta1.84
  • YTD % Change-10.69

RATIOS/PROFITABILITY

  • EPS (TTM)-1.87
  • P/E (TTM)-13.00
  • Fwd P/E (NTM)-4.41
  • EBITDA (TTM)-156.473M
  • ROE (TTM)-15.46%
  • Revenue (TTM)377.709M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-35.09%
  • Debt To Equity (MRQ)0.05%

EVENTS

  • Earnings Date05/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beam Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it...
John Evans
Chief Executive Officer, Director
Giuseppe Ciaramella Ph.D.
President
Terry-Ann Burrell
Chief Financial Officer, Treasurer
Address
238 Main Street
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
CPRX
Catalyst Pharmaceuticals Inc
15.34-0.66-4.12%
VCYT
Veracyte Inc
19.20+0.34+1.80%
DNLI
Denali Therapeutics Inc
16.60-0.22-1.31%
TGTX
TG Therapeutics Inc
13.99+0.17+1.23%
DNA
Ginkgo Bioworks
0.9246+0.053+6.0808%